A recent study found that a blood-thinning drug may protect cartilage and reduce inflammation and pain in cases of osteoarthritis, in a result described by researchers as promising.
Osteoarthritis is the most common joint disease, causing pain and stiffness when the cartilage covering the ends of bones wears away.
There are currently no approved drugs to stop or slow the disease, but a new study has identified a promising development from an unexpected source: a blood thinning drug.
Researcher Chuan-Ju Liu from Yale School of Medicine led a team that examined about 980 approved drugs to look for compounds that suppress disease-causing inflammatory signals. Three drugs stood out, and then one was chosen: dabigatran, a blood thinner used to prevent blood clots and strokes.
The researchers tested the drug on mice and macaques with surgically induced osteoarthritis; it was injected directly into the joints of the mice, while the monkeys received it orally.
The results, published in the journal Science Translational Medicine, were encouraging: the drug reduced cartilage damage and signs of inflammation in mice, and the animals exhibited less pain-related behavior and greater freedom of movement. In monkeys, the drug helped preserve cartilage, improved walking ability, and reduced abnormal bone stiffness beneath the cartilage.
The researchers found that dabigatran affects a protein called BIG2 that controls the movement of cell surface receptors. It affected two receptors, TNFR1 and IL-1R1, in two different ways to reduce inflammation, making the cells less responsive to the two inflammatory signals.
The researchers said this regulation represents a previously unknown approach to curbing inflammation and restoring the balance of cartilage cells.
The treatment has not yet been tested on patients with osteoarthritis, and there are concerns that dabigatran could cause bleeding. Researchers said that comprehensive safety studies assessing the risk of infection, bleeding, and long-term tolerability will be required before clinical application.
what is your opinion on this news ?do let us know in the comments on tha comment box
if you liked this news article please share on friends & family & don't forget to follow on website & social media


